Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15274 | 1.00 | TDP1 (0.35) | TDP1ECE1ALOX15BLMPMP22 | |
| Trifluoroacetic Acid SCHEMBL28921331 | 0.88 | NOS1 (0.33) | NOS2NOS1 | |
| SCHEMBL10349045 | 0.83 | TDP1 (0.37) | TDP1ECE1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL149117 | 0.82 | ECE1 (0.32) | ECE1ALOX15BLMPMP22KMT2A | |
| SCHEMBL28531439 | 0.82 | ECE1 (0.32) | ECE1ALOX15BLMPMP22KMT2A | |
| SCHEMBL14393213 | 0.81 | TDP1 (0.35) | TDP1ALOX15BLMPMP22CHRNB2 | |
| SCHEMBL17772929 | 0.80 | ECE1 (0.31) | ECE1ALOX15BLMPMP22KMT2A | |
| SCHEMBL6006627 | 0.80 | TDP1 (0.43) | TDP1GABRR1 | |
| SCHEMBL196267 | 0.80 | TDP1 (0.43) | TDP1GABRR1 | |
| SCHEMBL196268 | 0.80 | TDP1 (0.43) | TDP1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115301218-B | Lignocellulose sponge-based waste gas adsorption material and application thereof | 江苏宿迁润泰环保科技有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-115301218-A | Waste gas adsorbing material based on lignocellulose sponge and application thereof | 江苏宿迁润泰环保科技有限公司 | 2022-11-08 | — | — | CN | claimed |
| US-20160244484-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2016-08-25 | — | — | US | claimed |
| EP-3049428-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) | 2016-08-03 | — | — | EP | claimed |
| WO-2015040235-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-03-26 | — | — | WO | claimed |
| CN-118201966-A | Human transferrin receptor binding antibody-peptide conjugates | 肽梦想株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-118159298-A | Method for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118055773-A | Lipopeptides inhibitors of interleukin-23 receptor | 詹森生物科技公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-117980320-A | Bicyclic peptide inhibitors of interleukin-23 receptor | 詹森生物科技公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117957240-A | Human transferrin receptor binding peptides | 肽梦想株式会社 | 2024-04-30 | — | — | CN | disclosed |
| CN-115301218-B | Lignocellulose sponge-based waste gas adsorption material and application thereof | 江苏宿迁润泰环保科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-116801910-A | Means and methods for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1554394-A2 | ASPARAGINYL HYDROXYLASES AND MODULATORS THEREOF | ISIS INNOVATION LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004035812-A2 | ASPARAGINYL HYDROXYLASES AND MODULATORS THEREOF | ISIS INNOVATION LIMITED (GB) | 2004-04-29 | — | — | WO | disclosed |
| EP-0948523-B1 | PEPTIDOMIMETIC INHIBITORS OF THE HUMAN CYTOMEGALOVIRUS PROTEASE | BOEHRINGER INGELHEIM CA LTD (CA) | 2004-03-17 | — | — | EP | disclosed |
| US-6333402-B1 | FOR THERAPY AND DIAGNOSIS | DYAX CORP. | 2001-12-25 | — | — | US | disclosed |
| US-6057287-A | KUNITZ DOMAIN HAVING DISULFIDE BONDS AT CYSTINE 5-55, 14-38, 30-51 POSITIONS | DYAX CORP. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0383190-B1 | Ribonucleotide reductase inhibitors | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1995-06-14 | — | — | EP | disclosed |
| EP-0438873-A1 | Inhibitor of ribonucleotide reductase of herpes viruses | MERCK & CO. INC. (US) | 1991-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244484-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | VIP, TNF, ENPEP | TDP1 2255/4885ECE1 352/4885ALOX15 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.